1、Enhancing the Success Rate of Anticancer Drug R&D for Asian Populations – Primary Tumor Cell Bank from Chinese Patients Enables Accurate Preclinical Efficacy Prediction

• Industry Pain Point: Traditional commercial cell lines are mostly derived from European and American populations, with ethnic differences leading to a disconnect between drug efficacy prediction and clinical outcomes.
• Value Proposition: The primary tumor cell bank from Chinese patients accurately simulates the tumor microenvironment of Asian populations, significantly improving the accuracy of preclinical efficacy evaluation and reducing R&D risks.

2、Service Overview

1. Positioning: Asian primary tumor cell lines are core tools for preclinical candidate drug screening, especially for cancer types with a high incidence in Asian populations (e.g., liver cancer, gastric cancer).
2. Industry Pain Point: Commercial cell lines lack the genetic background of Asian populations, failing to truly reflect drug responses and increasing the risk of clinical trial failure.
3. Core Objective: Relying on a primary tumor cell bank 100% derived from Chinese patients, we provide highly clinically relevant efficacy models, shortening the R&D cycle by 30% and reducing the uncertainty of clinical translation.

3、Our Services

1. Cell Line Supply
   • Cancer Type Coverage: Covering 15 types of high-incidence tumors including liver cancer (38 cell lines), lung cancer (81 cell lines), and gastric cancer (14 cell lines).
   • Cell Characteristics: Retaining the pathological features of the original tumor (e.g., gene mutation, drug resistance) to support personalized drug screening.

2. Cellular Functional Assays

• Proliferation/Toxicity: MTT/CCK-8/CTG assays for evaluating drug activity.
• Migration/Invasion: Transwell assays for assessing the inhibitory effect on tumor metastasis.

3. Drug Sensitivity Screening

• High-Throughput Platform: Supporting 96-well plate screening and providing key data such as IC50 and dose-response curves.
• Molecular and Protein Platform: Targeted precise localization detection.

4、Technical Platforms and Advantages

1. Technical Platforms

• Primary Cell Line Establishment Technology: PDX model construction from clinical samples, isolation and culture of primary cells from tumor tissues, and cell line establishment; STR identification ensures the uniqueness of cell identity.
• Gene Editing Support: CRISPR-Cas9 technology for constructing gene-modified models (e.g., drug-resistant cell lines) to adapt to targeted drug R&D.

2. Infrastructure

• GMP-Grade Cell Bank: Ten-thousand-class clean culture rooms + BSL-2 laboratories to ensure contamination-free and high-activity cells.
• Quality Control System: 9-locus one-step STR locus detection and mycoplasma screening, complying with international standards.

3. Differentiated Advantages

• The Only Focus on Asian Populations: 100% derived from Chinese patients, covering rare mutation types (e.g., HBV-related liver cancer).
• End-to-End Service: One-stop solution for R&D needs from cell supply to efficacy reporting.

5、Service Process

1. Requirement Consultation: Response within 24 hours and provision of customized cell line screening protocols (e.g., cancer type, mutation type).
2. Cell Delivery: Provision of STR identification reports, culture guidelines, and cryopreserved cells (Passages 5–10).
3. Experiment Execution: Real-time sharing of test progress (e.g., CTG proliferation curves, invasion assay results).
4. Data Delivery: Provision of GLP-aligned standard reports within 7–14 days, including raw data and statistical analysis.

6、Quality Control and Compliance

Compliance Standards: Adhering to the ISO 9001 quality management system with traceable experimental data.

Quality Control Measures:

• Cell Identity Verification: STR detection.
• Aseptic Assurance: Mycoplasma/PCR detection.

Sample Ethics: All samples are obtained with informed consent from patients, in compliance with the Regulations on the Administration of Biological Sample Resources.

7、Case Studies

Case 1: Liver Cancer Targeted Drug Screening

• Cell Model: Primary liver cancer cell lines from Chinese patients (HBV+).
• Result: Lenvatinib-sensitive cell lines were screened out with an in vivotumor inhibition rate of 70%.
• Data Support: Tumor growth curves and tumor weight comparison charts (see the figure below).

Case 2: Gastric Cancer Chemoresistance Research

Cell Model: Oxaliplatin-resistant cell line (derived from the MKN45 cell line).

Result: The drug-resistant gene ABCG2 was identified, guiding the combination medication regimen (40% increase in TGI).

8、Cooperation Advantages

• Customization: Provision of cell lines with specific mutation types (e.g., EGFR L858R) according to the needs of pharmaceutical companies.
• Efficiency: Sufficient stock in the cell bank, with a delivery cycle 30% faster than the industry average.
• Full-Cycle Support: Covering early screening → mechanism research → IND application data support.

9、FAQ

• Q1: Is the cell line compatible with specific gene mutations?
  • Custom screening is supported (e.g., HER2+ gastric cancer), with mutation type information required to be provided.
• Q2: Is in vitro and in vivo efficacy linkage service provided?
  • PDX models can be integrated for in vivo efficacy validation.
• Q3: Can the data be used for FDA/EMA applications?
  • GLP-aligned standard reports are provided, complying with the data requirements for preclinical research.

10、Laboratory Highlights

Core Facilities:

• Ten-thousand-class clean room, processing over 100 samples daily.
• 9-locus one-step identification with an accuracy rate of >99%.

11、Contact Us

Consult Now:

• Email: 3691125803@qq.com
• Tel: +86 18802035152